Drug
PF-04136309
PF-04136309 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
3
60%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_2
Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes
NCT01226797
completedphase_2
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee
NCT00689273
terminatedphase_2
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
NCT02732938
completedphase_1
Food Effect Study PF-04136309
NCT02598206
completedphase_1
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT01413022
Clinical Trials (5)
Showing 5 of 5 trials
NCT01226797Phase 2
Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes
NCT00689273Phase 2
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee
NCT02732938Phase 2
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
NCT02598206Phase 1
Food Effect Study PF-04136309
NCT01413022Phase 1
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5